Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.

Diseases

Genetic and Rare Diseases Information Center (GARD)

Print friendly version

Spinocerebellar ataxia 2


Other Names for this Disease

  • Olivopontocerebellar atrophy 2
  • Olivopontocerebellar atrophy Holguin type
  • SCA 2
  • SDSEM
  • Spinocerebellar ataxia Cuban type
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

Your Question

Is there a cure for spinocerebellar ataxia type 2? How can I learn more about clinical trials involving new treatments for spinocerebellar ataxia type 2?

Our Answer

We have identified the following information that we hope you find helpful. If you still have questions, please contact us.

Is there a cure for spinocerebellar ataxia type 2?

At this time there is not a cure for spinocerebellar ataxia type 2.
Last updated: 1/31/2014

How might spinocerebellar ataxia 2 be treated?

Treatment of spinocerebellar ataxia 2 (SCA2) is supportive and aims to help the affected person maintain their independence and avoid injury. It is recommended that people with SCA2 remain physically active, maintain a healthy weight, use adaptive equipment as needed, and avoid alcohol and medications that affect cerebellar function. Adaptive equipment may include canes or other devices to help with walking and mobility. People with SCA2 may develop difficulty speaking and may need to use computerized devices or writing pads to help with communication. Levodopa may be prescribed to help with some of the movement problems (e.g., rigidity and tremor), and magnesium may improve muscle cramping.[1][2][3]
Last updated: 1/31/2014

How can I learn more about clinical trials investigating new therapies for spinocerebellar ataxia type 2?

The U.S. National Institutes of Health, through the National Library of Medicine, developed ClinicalTrials.gov to provide patients, family members, and members of the public with current information on clinical research studies. Currently, clinical trials are identified as enrolling individuals with spinocerebellar ataxia type 2. To view results from a sample search, click here. Click on the study titles to learn more. After you click on a study, review its "eligibility" criteria to determine its appropriateness. Use the study’s contact information to learn more. Check this site often for regular updates.

You can also contact the Patient Recruitment and Public Liaison (PRPL) Office at the National Institutes of Health (NIH). We recommend calling the toll-free number listed below to speak with a specialist, who can help you determine if you are eligible for any clinical trials.

Patient Recruitment and Public Liaison Office
NIH Clinical Center Bethesda, Maryland 20892-2655
Toll-free: 800-411-1222
Fax: 301-480-9793
Email: prpl@mail.cc.nih.gov
Web site: http://clinicalcenter.nih.gov/  

If you are interested in enrolling in a clinical trial, you can find helpful general information on clinical trials at the following ClinicalTrials.gov Web page.
http://clinicaltrials.gov/ct2/info/understand

A tutorial about clinical trials that can also help answer your questions can be found at the following link from the National Library of Medicine:
http://www.nlm.nih.gov/medlineplus/tutorials/cancerclinicaltrials/htm/lesson.htm

Resources on many charitable or special-fare flights to research and treatment sites and low-cost hospitality accommodations for outpatients and family members, as well as ambulance services, are listed on the Web site of the Office of Rare Diseases Research (ORDR), part of the National Institutes of Health.
http://rarediseases.info.nih.gov/Resources.aspx?PageID=8

Last updated: 1/31/2014

References
Other Names for this Disease
  • Olivopontocerebellar atrophy 2
  • Olivopontocerebellar atrophy Holguin type
  • SCA 2
  • SDSEM
  • Spinocerebellar ataxia Cuban type
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.